Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN)’s shares declined 0.81% to $1.22. The company on Mar. 10 announced initial data for the Phase I dose-escalation clinical trial of SupinoxinTM (RX-5902) initiated in August 2013. This trial was designed to study safety and efficacy in patients with solid cancer tumors. The study is still ongoing and the maximal tolerated dose (MTD) has not yet been achieved. Three dosing cycles have been completed (25, 50 and 100 mg) and no drug related adverse events have been reported. The fourth dosing cycle (150 mg) has been initiated. Two patients have received 2 cycles of treatment and one patient has received 6 cycles of treatment. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) stock opened today at $1.25 and is currently trading at $1.29. The stock showed a negative weekly performance of -7.58%.
Neuralstem, Inc. (NYSEMKT:CUR) Positive News Reports Sends Stock Moving Upwards Neuralstem, Inc. (NYSEMKT:CUR) was up 8.33 percent during trading on 13th March on the back of positive reviews the company’s test drug code named NSI 566 has received in the business magazines and other pharma related forums. The drug which is currently undergoing phase 2 testing to treat Lou Gehrigs disease, which leads to a progressive deterioration in the neuro motor communication, which in turn would lead to a vegetative state has ensured a big interest in the updates that the drug maker provides on the progress of its phase 2 testing. The small capped firm is aiming for a “break through drug” designation from FDA for this drug candidate. Neuralstem, Inc. (NYSEMKT:CUR) stock opened at $4.11, in current trading session and currently is at $4.37, by gaining 9.49%.The 52 week range of $1.00-$4.37.Company’s market capitalization is $369.01 million.
CytRx Corporation (Nasdaq: CYTR) announced the appointment of Felix Kratz, Ph.D. as Vice President of Drug Discovery and André Warnecke, Ph.D. as Senior Director of Drug Discovery. Drs. Kratz and Warnecke and their scientific team will expand the Corporation’s novel albumin-binding anti-cancer drug pipeline. CytRx Corporation (NASDAQ:CYTR) stock is currently trading at $4.48 .The EPS of the stock is -1.34. Company’s market capitalization is $236.98 million.
Celgene Corporation (NASDAQ:CELG) stock opened the session at $150.82, and now is at $153.69. The 52 week range of the CELG stock remained $108.01-$174.66 and the day range was $149.85-$153.69.